64.66 -0.11 (-0.16%)
After hours: 4:04PM EDT
|Bid||64.29 x 1200|
|Ask||64.75 x 900|
|Day's Range||64.20 - 65.50|
|52 Week Range||48.05 - 65.50|
|PE Ratio (TTM)||242.51|
|Earnings Date||Jul 18, 2018|
|Forward Dividend & Yield||1.12 (1.83%)|
|1y Target Est||68.94|
Earnings and more commentary from Federal Reserve chair Jerome Powell will be the highlights for investors on Wednesday after tech stocks closed at a record high on Wednesday.
Abbott (ABT) posts another quarter of strong EPD and Medical Devices performance. Particularly, Abbott has been riding high on a healthy growth within its Diabetes Care business.
Prices might retest the flat 50-day moving average line but a bullish OBV line is probably foreshadowing higher prices for ABT in the months ahead." Let's look at some new charts for price targets and risk points. The daily On-Balance-Volume (OBV) line has been rising since last August and is just short of a new high. A rising OBV line is a sign of aggressive buying.
ABT Stock Trading at a Record High on Stellar Q2 2018 ResultsABT’s second-quarter earnings trigger stock price rise
This is an increase over its earnings per share of 62 cents from the same time last year. It also beat out Wall Street’s earnings per share estimate of 71 cents for the quarter, making it a boon to ABT stock. Net income reported by Abbott Laboratories for the second quarter of 2018 came in at $733 million.
A strong U.S. dollar was no match for Abbott Laboratories. Shares of the medical device maker shrugged off concerns over the strengthening currency and reached a record after the company announced second-quarter earnings that beat analyst expectations. "We forecast continued strong performance and are raising our full-year outlook despite recent currency shifts," Chief Executive Officer Miles White said in a statement.
Morgan Stanley, U.S. Bank and Abbott all beat expectations, but new Housing Starts and Permits numbers were far below expectations.
Among the companies with shares expected to trade actively in Wednesday's session are Alphabet, Morgan Stanley, Texas Instruments, United Continental Holdings and Boeing.
Netflix (NASDAQ:NFLX) ended the day down to the tune of 5% after it fell short of subscriber-growth outlooks for the recently ended quarter. Among the best of those best are Leggett & Platt (NYSE:LEG), Abbott Laboratories (NYSE:ABT) and United Technologies (NYSE:UTX). During the first quarter of the year, Leggett & Platt shareholders had good reason to be worried.
The Abbott Park, Ill., healthcare company beats top- and bottom-line estimates and raises its full-year outlook for earnings.